Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL8924228 | 0.93 | IDO1 (0.67) | IDO1KMT2AMAOBTAAR1PTPN2 | |
| SCHEMBL5780375 | 0.89 | IDO1 (0.57) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL668193 | 0.89 | IDO1 (0.57) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL8076361 | 0.87 | IDO1 (0.59) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL3434078 | 0.87 | IDO1 (0.59) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL1771605 | 0.87 | IDO1 (0.59) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL29226719 | 0.87 | IDO1 (0.59) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL10458621 | 0.85 | IDO1 (0.57) | IDO1KMT2AMAOBTAAR1TACR1 | |
| SCHEMBL17298962 | 0.84 | MGLL (0.68) | IDO1KMT2AMAOBPTPN2PTPN1 | |
| SCHEMBL2399721 | 0.84 | TRPV6 (0.68) | IDO1KMT2AMAOBTAAR1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546162-B1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2011-06-22 | — | — | EP | claimed |
| US-7692022-B2 | Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations | PROMEGA CORPORATION (US) | 2010-04-06 | — | — | US | claimed |
| EP-1546162-A4 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2007-07-18 | — | — | EP | claimed |
| EP-1546162-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040171099-A1 | Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations | PROMEGA CORPORATION | 2004-09-02 | — | — | US | claimed |
| WO-2004027378-A2 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170191985-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-07-06 | — | — | US | disclosed |
| US-9574223-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140380514-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2014-12-25 | — | — | US | disclosed |
| US-8765969-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-8106052-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | PROMEGA CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1546162-B1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | PROMEGA CORP (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20020040136-A1 | Vitronectin receptor antagonist | SMITHKLINE BEECHAM CORPORATION | 2002-04-04 | — | — | US | disclosed |
| US-20010014737-A1 | Vitronectin receptor antagonist | HEERDING DIRK (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1017387-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0957917-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999015170-A1 | VITRONECTIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
| US-4169152-A | Isohexide and tetrahydrofuran ethers and their carbamates in method of bringing about relaxation of skeletal musculature | ICI AMERICAS INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040136-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | IDO1 4221/4885KMT2A 4439/4885MAOB 3271/4885 |
| US-20140380514-A1 | LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY | CYP3A43, CYP3A7, CYP3A5 | IDO1 718/4885KMT2A 4413/4885MAOB 241/4885 |
| US-20010014737-A1 | Vitronectin receptor antagonist | CALCR, ADGRF1, CALCRL | IDO1 4221/4885KMT2A 4439/4885MAOB 3271/4885 |
| US-10408819-B2 | Luminescence-based methods and probes for measuring cytochrome P450 activity | CYP3A7, CYP3A43, CYP3A5 | IDO1 593/4885KMT2A 3905/4885MAOB 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.